MBX (MBX Biosciences) Total Liabilities: $14.95 Mil (As of Mar. 2026)


MBX MBX Biosciences Inc MBX
12 GF Score
Price $52.21
! 2 Warning Signs
View Full Analysis

What is MBX Biosciences Total Liabilities?

MBX Biosciences MBX +3.77% 12 Total Liabilities is $14.95 Mil as of Mar. 2026. GuruFocus rates MBX with a GF Score™ of 12/100. The stock has 2 warning signs investors should review.

MBX Biosciences's Total Liabilities for the quarter that ended in Mar. 2026 was $14.95 Mil.

MBX Biosciences's quarterly Total Liabilities increased from Sep. 2025 ($12.54 Mil) to Dec. 2025 ($15.92 Mil) but then declined from Dec. 2025 ($15.92 Mil) to Mar. 2026 ($14.95 Mil).

MBX Biosciences's annual Total Liabilities declined from Dec. 2023 ($156.65 Mil) to Dec. 2024 ($11.09 Mil) but then increased from Dec. 2024 ($11.09 Mil) to Dec. 2025 ($15.92 Mil).

MBX Biosciences Total Liabilities Historical Data

* Premium members only.

The historical data trend for MBX Biosciences's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MBX Biosciences Total Liabilities Chart

MBX Biosciences Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Total Liabilities
87.70 156.65 11.09 15.92

MBX Biosciences Quarterly Data
Dec22 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.50 12.28 12.54 15.92 14.95
MBX
12GF Score
MBX Biosciences Inc MBX
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MBX Biosciences Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

MBX Biosciences's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=15.495+(0.424+0.0020000000000002
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=15.92

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=385.144-369.223
=15.92

MBX Biosciences's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=14.567+(0.377+0.0010000000000001
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=14.95

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=452.701-437.756
=14.95

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $14.95 Mil mean?
MBX Biosciences (MBX) has a Total Liabilities of $14.95 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for MBX Biosciences and its competitors.
Is MBX Biosciences' Total Liabilities too high?
MBX Biosciences' current Total Liabilities is $14.95 Mil. Overall, MBX Biosciences has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does MBX Biosciences' Total Liabilities compare to ARDX and INBX?
MBX Biosciences' Total Liabilities of $14.95 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for MBX Biosciences and its competitors. MBX Biosciences's current Total Liabilities is $14.95 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MBX Biosciences stock overvalued right now?
MBX Biosciences (MBX) has a current Total Liabilities of $14.95 Mil. The current Total Liabilities is $14.95 Mil. MBX Biosciences' overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For MBX Biosciences (MBX), the current Total Liabilities is $14.95 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MBX Biosciences Business Description

Address 11711 N. Meridian Street, Suite 300, Carmel, IN, USA, 46032
MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include canvuparatide (MBX 2109), imapextide (MBX 1416), and MBX 4291.
12GF Score

Get the complete analysis for MBX

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$52.21
Price